Initial Experience with the Derivo 2Heal Flow Diverter under Standard or Reduced-Dose Single Antiplatelet Therapy

References

1. 1.↵
   1. Dandapat S,
   2. Mendez-Ruiz A,
   3. Martínez-Galdámez M, et al

   . Review of current intracranial aneurysm flow diversion technology and clinical use. J Neurointerv Surg 2021;13:54–62 doi:10.1136/neurintsurg-2020-015877 pmid:32978269

   Abstract/FREE Full Text
2. 2.↵
   1. Monteiro A,
   2. Burke SM,
   3. Baig AA, et al

   . A systematic review and meta-analysis of the Derivo Embolization Device: a novel surface-modified flow diverter for intracranial aneurysm treatment. J Neurointerv Surg 2022;14:1125–9 doi:10.1136/neurintsurg-2021-018390 pmid:35232753

   Abstract/FREE Full Text
3. 3.↵
   1. Panchendrabose K,
   2. Muram S,
   3. Mitha AP

   . Promoting endothelialization of flow-diverting stents: a review. J Neurointerv Surg 2021;13:86–90 doi:10.1136/neurintsurg-2020-015874 pmid:32487770

   Abstract/FREE Full Text
4. 4.↵
   1. Hudson JS,
   2. Lang MJ,
   3. Gross BA

   . Novel innovation in flow diversion: surface modifications. Neurosurg Clin N Am 2022;33:215–18 doi:10.1016/j.nec.2021.11.004 pmid:35346453

   CrossRefPubMed
5. 5.↵
   1. White TG,
   2. Santhumayor BA,
   3. Turpin J, et al

   . Flow diverter surface modifications for aneurysm treatment: a review of the mechanisms and data behind existing technologies. Interv Neuroradiol [Epub ahead of print] October 29, 2023. doi:10.1177/15910199231207550 pmid:37899636

   CrossRefPubMed
6. 6.↵
   1. Batur H,
   2. Topcuoglu MA,
   3. Balci S, et al

   . Dual testing to achieve low on-treatment platelet reactivity for aneurysm embolization. Clin Neuroradiol 2021;31:1159–65 doi:10.1007/s00062-021-01011-7 pmid:33844028

   CrossRefPubMed
7. 7.↵
   1. Link A,
   2. Michel T,
   3. Schaller M, et al

   . In vitro investigation of an intracranial flow diverter with a fibrin-based, hemostasis mimicking, nanocoating. Biomed Mater 2020;16:015026 doi:10.1088/1748-605X/abc8d3 pmid:33166946

   CrossRefPubMed
8. 8.↵
   1. Mühl-Benninghaus R,
   2. Fries F,
   3. Kießling M, et al

   . Vascular response on a novel fibrin-based coated flow diverter. Cardiovasc Intervent Radiology 2022;45:236–43 doi:10.1007/s00270-021-03007-9 pmid:34913987

   CrossRefPubMed
9. 9.↵
   1. Fang H,
   2. Peng S,
   3. Chen A, et al

   . Biocompatibility studies on fibrin glue cultured with bone marrow mesenchymal stem cells in vitro. J Huazhong Univ Sci Technolog Med Sci 2004;24:272–74 doi:10.1007/BF02832010 pmid:15315346

   CrossRefPubMed
10. 10.↵
    1. Barsotti MC,
    2. Felice F,
    3. Balbarini A, et al

    . Fibrin as a scaffold for cardiac tissue engineering. Biotechnol Appl Biochem 2011;58:301–10 doi:10.1002/bab.49 pmid:21995533

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Kaplan O,
    2. Hierlemann T,
    3. Krajewski S, et al

    . Low-thrombogenic fibrin-heparin coating promotes in vitro endothelialization. J Biomed Mater Res A 2017;105:2995–3005 doi:10.1002/jbm.a.36152 pmid:28646555

    CrossRefPubMed
12. 12.↵
    1. Janmey PA,
    2. Winer JP,
    3. Weisel JW

    . Fibrin gels and their clinical and bioengineering applications. J R Soc Interface 2009;6:1–10 doi:10.1098/rsif.2008.0327 pmid:18801715

    CrossRefPubMed
13. 13.↵
    1. Barker TH,
    2. Engler AJ

    . The provisional matrix: setting the stage for tissue repair outcomes. Matrix Biol 2017;60-61:1–4 doi:10.1016/j.matbio.2017.04.003 pmid:28527902

    CrossRefPubMed
14. 14.↵
    1. Li JJ,
    2. Zreiqat H

    . Tissue response to biomaterials. In: Encyclopedia of Biomedical Engineering. Elsevier; 2019:270–77
15. 15.↵
    1. Anderson JM

    . Biological responses to materials. Annu Rev Mater Res 2001;31:81–110 doi:10.1146/annurev.matsci.31.1.81

    CrossRef
16. 16.↵
    1. Shaikh FM,
    2. Callanan A,
    3. Kavanagh EG, et al

    . Fibrin: a natural biodegradable scaffold in vascular tissue engineering. Cells Tissues Organs 2008;188:333–46 doi:10.1159/000139772 pmid:18552484

    CrossRefPubMed
17. 17.↵
    1. Grüter BE,
    2. Wanderer S,
    3. Strange F, et al

    . Patterns of neointima formation after coil or stent treatment in a rat saccular sidewall aneurysm model. Stroke 2021;52:1043–52 doi:10.1161/STROKEAHA.120.032255 pmid:33504186

    CrossRefPubMed
18. 18.↵
    1. Patel SD,
    2. Waltham M,
    3. Wadoodi A, et al

    . The role of endothelial cells and their progenitors in intimal hyperplasia. Ther Adv Cardiovasc Dis 2010;4:129–41 doi:10.1177/1753944710362903 pmid:20200200

    CrossRefPubMed
19. 19.↵
    1. Yang Z,
    2. Tu Q,
    3. Wang J, et al

    . The role of heparin binding surfaces in the direction of endothelial and smooth muscle cell fate and re-endothelialization. Biomaterials 2012;33:6615–25 doi:10.1016/j.biomaterials.2012.06.055 pmid:22784604

    CrossRefPubMed
20. 20.↵
    1. Srinivasan S,
    2. Sawyer PN

    . Correlation of the surface charge characteristics of polymers with their antithrombogenic characteristics. Journal of Macromolecular Science: Part A - Chemistry 1970;4:545–60 doi:10.1080/00222337008074362

    CrossRef
21. 21.↵
    1. Siedlecki CA

    1. Amoako K,
    2. Gbyli R

    . 9 - Improving the hemocompatibility of biomedical polymers. In: Siedlecki CA, ed. Hemocompatibility of Biomaterials for Clinical Applications. Woodhead Publishing; 2018:223–252
22. 22.↵
    1. Shan L,
    2. Sun Y,
    3. Shan F, et al

    . Recent advances in heparinization of polymeric membranes for enhanced continuous blood purification. J Mater Chem B 2020;8:878–94 doi:10.1039/c9tb02515d pmid:31956883

    CrossRefPubMed
23. 23.↵
    1. Panchendrabose K

    . Evaluation of In Vivo Endothelialization of VEGF Coated Stents with Allogeneic Mesenchymal Stem Cells. Thesis, University of Calgary. 2020.
24. 24.↵
    1. Thormann M,
    2. Sillis N,
    3. Thoma T, et al

    . The DERIVO®2 Embolization Device in the treatment of ruptured and unruptured intracranial aneurysms: a multicenter analysis. Interv Neuroradiol [Epub ahead of print] December 25, 2022. doi:10.1177/15910199221142643 pmid:36567499

    CrossRefPubMed
25. 25.↵
    1. Piano M,
    2. Lozupone E,
    3. Sgoifo A, et al

    ; Italian DERIVO® Registry Group. Long-term follow-up of the Derivo® Embolization Device (DED®) for intracranial aneurysms: the Italian Multicentric Registry. J Neurosurg Sci 2021;65:361–68 doi:10.23736/S0390-5616.21.05300-5 pmid:33879762

    CrossRefPubMed
26. 26.↵
    1. Piñana C,
    2. Remollo S,
    3. Zamarro J, et al

    . Derivo embolization device for intracranial aneurysms: a Spanish multicenter retrospective study. J Neurointerv Surg 2022;15:871–75 doi:10.1136/jnis-2022-019220 pmid:35999049

    Abstract/FREE Full Text
27. 27.↵
    1. Hanel RA,
    2. Kallmes DF,
    3. Lopes DK, et al

    . Prospective study on embolization of intracranial aneurysms with the Pipeline device: the PREMIER study 1 year results. J Neurointerv Surg 2020;12:62–66 doi:10.1136/neurintsurg-2019-015091 pmid:31308197

    Abstract/FREE Full Text
28. 28.↵
    1. Yeomans J,
    2. Sandu L,
    3. Sastry A

    . Pipeline Flex embolisation device with Shield technology for the treatment of patients with intracranial aneurysms: periprocedural and 6 month outcomes. Neuroradiol J 2020;33:471–78 doi:10.1177/1971400920966749 pmid:33092461

    CrossRefPubMed
29. 29.↵
    1. Luo C,
    2. Jin L,
    3. Dong J, et al

    . Clinical outcomes of Pipeline embolization devices with Shield technology for treating intracranial aneurysms. Front Neurol 2022;13:971664 doi:10.3389/fneur.2022.971664 pmid:36452166

    CrossRefPubMed
30. 30.↵
    1. Martínez-Galdámez M,
    2. Lamin SM,
    3. Lagios KG, et al

    . Periprocedural outcomes and early safety with the use of the Pipeline Flex Embolization Device with Shield Technology for unruptured intracranial aneurysms: preliminary results from a prospective clinical study. J Neurointerv Surg 2017;9:772–76 doi:10.1136/neurintsurg-2016-012896 pmid:28223428

    Abstract/FREE Full Text
31. 31.↵
    1. Hellstern V,
    2. Aguilar Pérez M,
    3. Henkes E, et al

    . Use of a p64 MW flow diverter with hydrophilic polymer coating (HPC) and prasugrel single antiplatelet therapy for the treatment of unruptured anterior circulation aneurysms: safety data and short-term occlusion rates. Cardiovasc Intervent Radiology 2022;45:1364–74 doi:10.1007/s00270-022-03153-8 pmid:35562486

    CrossRefPubMed
32. 32.↵
    1. Winters H,
    2. Schüngel M-S,
    3. Scherlach C, et al

    . First experience of three neurovascular centers with the p64MW-HPC, a low-profile flow diverter designed for proximal cerebral vessels with antithrombotic coating. Front Neurol 2021;12:724705 doi:10.3389/fneur.2021.724705 pmid:34594297

    CrossRefPubMed
33. 33.↵
    1. Bhogal P,
    2. Petrov A,
    3. Rentsenkhu G, et al

    . Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment. Interv Neuroradiol 2022;28:266–76 doi:10.1177/15910199211029503 pmid:34233547

    CrossRefPubMed
34. 34.↵
    1. Bhogal P,
    2. Bleise C,
    3. Chudyk J, et al

    . The p48_HPC antithrombogenic flow diverter: initial human experience using single antiplatelet therapy. J Int Med Res 2020;48:300060519879580 doi:10.1177/0300060519879580 pmid:31612765

    CrossRefPubMed
35. 35.↵
    1. Ravindran K,
    2. Salem MM,
    3. Alturki AY, et al

    . Endothelialization following flow diversion for intracranial aneurysms: a systematic review. AJNR Am J Neuroradiol 2019;40:295–301 doi:10.3174/ajnr.A5955 pmid:30679207

    Abstract/FREE Full Text
36. 36.↵
    1. Lenz-Habijan T,
    2. Brodde M,
    3. Kehrel BE, et al

    . Comparison of the thrombogenicity of a bare and antithrombogenic coated flow diverter in an in vitro flow model. Cardiovasc Intervent Radiology 2020;43:140–46 doi:10.1007/s00270-019-02307-5 pmid:31410532

    CrossRefPubMed
37. 37.↵
    1. Li YL,
    2. Roalfe A,
    3. Chu EY, et al

    . Outcome of flow diverters with surface modifications in treatment of cerebral aneurysms: systematic review and meta-analysis. AJNR Am J Neuroradiol 2021;42:327–33 doi:10.3174/ajnr.A6919 pmid:33384292

    Abstract/FREE Full Text
38. 38.↵
    1. Pierot L,
    2. Lamin S,
    3. Barreau X, et al

    . Coating (Coating to Optimize Aneurysm Treatment in the New Flow Diverter Generation) study. The first randomized controlled trial evaluating a coated flow diverter (p64 MW HPC): study design. J Neurointerv Surg 2022;15:684–88 doi:10.1136/neurintsurg-2022-018969 pmid:35609974

    Abstract/FREE Full Text
39. 39.↵
    1. Halitcan B,
    2. Bige S,
    3. Sinan B, et al

    . The implications of magnetic resonance angiography artifacts caused by different types of intracranial flow diverters. J Cardiovasc Magn Reson 2021;23:69 doi:10.1186/s12968-021-00753-0 pmid:34092251

    CrossRefPubMed